Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928576 · ClinicalTrials.gov registry record · Phase 2
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT01928576 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 143 participants.
The verdict
NCT01928576, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
Response Rate
Interventions
- DRUG Azacitidine
- DRUG Nivolumab
- DRUG Entinostat
- DRUG CC-486 300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-11-06 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928576
The ClinicalTrials.gov registry entry for NCT01928576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Azacitidine is the first listed.
NCT01928576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928576 about?
NCT01928576 is a clinical study titled "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.". Response Rate
What is the current status of trial NCT01928576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2013-11-06. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT01928576?
The interventions under investigation include: Azacitidine (DRUG), Nivolumab (DRUG), Entinostat (DRUG), CC-486 300 (DRUG).
Who is sponsoring clinical trial NCT01928576?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.